<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01783717</url>
  </required_header>
  <id_info>
    <org_study_id>2012-217</org_study_id>
    <nct_id>NCT01783717</nct_id>
  </id_info>
  <brief_title>Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage</brief_title>
  <official_title>Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of exenatide on body weight and glycemic&#xD;
      control in subjects with obesity and/or diabetes mellitus due to hypothalamic damage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hypothalamus lesion caused by tumors in the hypothalamic region, such as&#xD;
      craniopharyngioma and germ cell tumors, and inflammatory diseases are susceptible to develop&#xD;
      severe obesity and diabetes mellitus. The occurrence of hypothalamic obesity in patients&#xD;
      after surgery with or without radiotherapy for craniopharyngioma can be as high as 42-66%,&#xD;
      and the incidence of type 2 diabetes mellitus of them is twice as much as healthy controls.&#xD;
      Treatment of obesity and diabetes mellitus in this population is crucial for increasing&#xD;
      morbidity and mortality. However, diet and exercise intervention has been proven useless in&#xD;
      previous studies. Safe and effective medicine remains to be developed. Exenatide, a GLP-1&#xD;
      receptor agonist, which play an antihyperglycemic role through a variety of mechanisms, such&#xD;
      as enhancing glucose-dependent insulin secretion, increasing beta cell mass and decreasing&#xD;
      glucagon secretion, possesses a potent ability to induce satiety, slow gastric emptying and&#xD;
      reduce food intake, resulting in weight loss both in diabetics and patients with simple&#xD;
      obesity. Previous animal study has already shown GLP-1 agonist exendin-4 leads to reduction&#xD;
      of weight and caloric intake in a rat model of hypothalamic obesity. Therefore, the&#xD;
      investigators hypothesize exenatide treatment might lead to weight loss in hypothalamic obese&#xD;
      patients and improve their glycemic control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight frome baseline to end of the study.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood glucose level.</measure>
    <time_frame>3 months.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta cell function.</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity.</measure>
    <time_frame>baseline and 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waistline</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of body fat</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of daily energy intake</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure (kcals per day)</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of metabolic equivalents (MET) scales</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hipline.</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waistline/hipline ratio</measure>
    <time_frame>baseline and 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypothalamic Obesity</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be between 18 and 55 years old;&#xD;
&#xD;
          2. Greater than 6 months post-treatment (including surgery, radiotherapy or chemotherapy)&#xD;
             of craniopharyngioma or other diseases in the hypothalamic region;&#xD;
&#xD;
          3. BMI≧28kg/m2 and/or diabetes mellitus;&#xD;
&#xD;
          4. Greater than 3 months after adequate replacement therapy for&#xD;
             hypothalamic-pituitary-adrenal (HPA) axis and hypothalamic-pituitary-thyroid (HPT)&#xD;
             axis;&#xD;
&#xD;
          5. Sign informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Less than 6 months post surgery or radiotherapy or chemotherapy for craniopharyngioma&#xD;
             or other diseases in the hypothalamic region;&#xD;
&#xD;
          2. Inadequate replacement for the HPA axis and HPT axis or undertaking adjustments of the&#xD;
             kind or dose of the substitutive medicine;&#xD;
&#xD;
          3. Use of weight loss drugs or initiation of a weight loss program within past 3 months;&#xD;
&#xD;
          4. Use of GLP-1 agonists or analogues or dipeptidyl peptidase IV (DPP-IV) inhibitors&#xD;
             within past 3 months;&#xD;
&#xD;
          5. History of bariatric surgery;&#xD;
&#xD;
          6. Diagnosed with simple obesity or diabetes mellitus prior to the hypothalamic&#xD;
             disorders, and those diagnosed with type 1 diabetes mellitus;&#xD;
&#xD;
          7. With end-stage-renal diseases or history of kidney transplant or complicated with&#xD;
             acute/chronic kidney failure (GFR≦30ml/min);&#xD;
&#xD;
          8. History of inflammatory bowel diseases or gastroparesis or other gastric mortility&#xD;
             problems;&#xD;
&#xD;
          9. History of pancreatitis or chronic cholecystitis;&#xD;
&#xD;
         10. History of allergic reaction to exenatide or other medication components;&#xD;
&#xD;
         11. Undertaking warfarin;&#xD;
&#xD;
         12. Pregnant or lactating women;&#xD;
&#xD;
         13. Are participating in, or have participated in other drug clinical trials within past 3&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li yi ming</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhang z yun</last_name>
    <phone>86-21-52888286</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye h ying</last_name>
      <phone>86-21-52887027</phone>
    </contact>
    <investigator>
      <last_name>Zhang z yun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>December 25, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>October 20, 2013</last_update_submitted>
  <last_update_submitted_qc>October 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoyun Zhang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

